checkAd
Navidea Biopharmaceuticals Aktie
ISIN: US63937X2027 · WKN: A2PH4J · SYM: NO1A
0,244
 
EUR
-12,23 %
-0,034 EUR
Letzter Kurs 18.01.23 · Tradegate

Neueste Nachrichten

Navidea Biopharmaceuticals Announces the Notice of Allowance for U.S. Patent Application for Key Component of the Company’s Cancer Immunotherapy Pipeline
03.01.23 · Business Wire (engl.) · Navidea Biopharmaceuticals
Navidea Biopharmaceuticals Files Appeal in CRG Case
01.12.22 · Business Wire (engl.) · Navidea Biopharmaceuticals
Navidea Biopharmaceuticals Announces 50th Participant Enrolled in the Company’s Phase 3 Trial in Rheumatoid Arthritis
28.11.22 · Business Wire (engl.) · Navidea Biopharmaceuticals
Navidea Biopharmaceuticals Reports Third Quarter 2022 Financial Results
14.11.22 · Business Wire (engl.) · Navidea Biopharmaceuticals
Navidea Biopharmaceuticals Announces Details of Presentation at Upcoming Society for Immunotherapy of Cancer Annual Meeting
07.11.22 · Business Wire (engl.) · Navidea Biopharmaceuticals
Navidea Biopharmaceuticals to Host Third Quarter 2022 Earnings Conference Call and Business Update
04.11.22 · Business Wire (engl.) · Navidea Biopharmaceuticals
Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at Upcoming Society for Immunotherapy of Cancer Annual Meeting
05.10.22 · Business Wire (engl.) · Navidea Biopharmaceuticals
Navidea Biopharmaceuticals Appoints Joshua Wilson to the Board of Directors; Announces Dates Related to its 2022 Annual Meeting of Stockholders
30.09.22 · Business Wire (engl.) · Navidea Biopharmaceuticals
Navidea Biopharmaceuticals Announces Presentation of Results from its Two Phase 2B Clinical Trials in Rheumatoid Arthritis at Upcoming American College of Rheumatology Annual Meeting
15.09.22 · Business Wire (engl.) · Navidea Biopharmaceuticals
Navidea Biopharmaceuticals Announces Opening of Nine New Sites in its Pivotal Phase 3 Trial in Rheumatoid Arthritis and Termination of Binding Memorandum of Understanding with Jubilant Radiopharma
01.09.22 · Business Wire (engl.) · Navidea Biopharmaceuticals
Navidea Biopharmaceuticals Announces Oral Ruling in Case Involving Attorney’s Fees
01.09.22 · Business Wire (engl.) · Navidea Biopharmaceuticals
 Navidea Biopharmaceuticals Announces Closing of its Rights Offering and Second Quarter 2022 Earnings Conference Call and Business Update
30.08.22 · Business Wire (engl.) · Navidea Biopharmaceuticals